Moderna (WBO:MRNA) Additional Paid-In Capital : €448 Mil(As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Moderna Additional Paid-In Capital?

Moderna's quarterly additional paid-in capital increased from Sep. 2023 (€260 Mil) to Dec. 2023 (€340 Mil) and increased from Dec. 2023 (€340 Mil) to Mar. 2024 (€448 Mil).

Moderna's annual additional paid-in capital declined from Dec. 2021 (€3,727 Mil) to Dec. 2022 (€1,107 Mil) and declined from Dec. 2022 (€1,107 Mil) to Dec. 2023 (€340 Mil).

Moderna Additional Paid-In Capital Historical Data

The historical data trend for Moderna's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Additional Paid-In Capital Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

2,402.48

3,947.24

3,726.74

1,107.31

340.21

Moderna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															682.75	178.14	259.55	340.21	448.04

Moderna Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Moderna Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Moderna's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (WBO:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (WBO:MRNA) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.